Drugs / Clostridium novyi-NT
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03435952 | Jul 2018 → Oct 2026 expected | breast cancer, cancer of unknown primary site, digestive system cancer, female reproductive organ cancer +7 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01924689 | Oct 2013 → Oct 2017 | — | BioMed Valley Discoveries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00358397 | Jul 2006 → Sep 2008 | neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium novyi-NT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00358397 ↗ |
| Known as | C. novyi-NT | “This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection of C. novyi-NT across 6...” PMID 33046513 ↗ Oct 20201“This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.” NCT00358397 ↗ |
| Modality | Other / unclassified | “Investigators at the SKCCC have developed a bacterial strain (C. novyi-NT) that can infect tumors and destroy them, but does not grow in normal tissues.” NCT00358397 ↗ |
| Route | Intravenous | “one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores” NCT00358397 ↗ |